Carrier - Bound Or Immobilized Peptides Or Proteins And The Preparation Thereof, E.g., Biological Cell Or Cell Fragment As Carrier, Etc. Patents (Class 530/810)
  • Patent number: 4745182
    Abstract: Disclosed are antibody substances displaying unique, multi-specific immunoreactivities with respect to glycoprotein D of Herpes Simplex Virus types 1 and 2 (HSV gD-1 and gD-2) and structurally related compounds. Illustratively, an IgG Type 2 monoclonal antibody material produced by mouse-mouse hybridoma cell line A.T.C.C. No. HB8606 is capable of in vitro neutralization of HSV-1 and HSV-2 infectivity and of specific immunological reactivity and reversible immunobinding with natrually-occuring and recombinant gD-1 and gD-2 in both native and denatured conformations as well as with proteinaceous materials (produced, e.g., by proteolytic digestion of naturally-occurring materials, by recombinant methods, or by polymerization of amino acids) which comprise a primary structural conformation substantially duplicating part or all of that which is predicted to be extant at residues 266 through 287 of gD-1 and gD-2 [i.e., PELA(or V)PEDPEDSALLEDPV(or A)GTVA(or S)].
    Type: Grant
    Filed: January 31, 1985
    Date of Patent: May 17, 1988
    Assignee: University Patents, Inc.
    Inventors: Gary H. Cohen, Roselyn J. Eisenberg
  • Patent number: 4743539
    Abstract: A new specific antibody to 5'-terminal mono-, di- or triphosphorylated (2'-5')adenyl-adenosine oligonucleotides and a method of producing it have been found. The antibody can be used for the quantitative analysis of the oligonucleotides mentioned above in any one of the well known methods of immunological analysis.
    Type: Grant
    Filed: November 9, 1984
    Date of Patent: May 10, 1988
    Inventors: Julian Gordon, Michael A. Minks
  • Patent number: 4740585
    Abstract: A vaccine effective in protecting mammals against urinary tract infections is prepared from synthetic peptides substantially equivalent to short sequences contained in HU849 pilin conjugated to substantially antigenically neutral carriers or from a CNBrII fragment of HU849 pilin.
    Type: Grant
    Filed: July 30, 1984
    Date of Patent: April 26, 1988
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: M. Alexander Schmidt, Peter O'Hanley, Gary K. Schoolnik
  • Patent number: 4722906
    Abstract: A method for selectively covalently linking a target moiety to a chemical moiety or carrier comprising attaching to the chemical moiety or carrier a reagent having a selector group capable of forming a specific bond with a receptor carried on the target moiety and attaching a latent reactive group which is capable upon activation of covalently bonding to the target moiety, reacting the selector group with the receptor on the target moiety, and activating the latent group to form a covalent linkage to the target moiety.
    Type: Grant
    Filed: September 29, 1982
    Date of Patent: February 2, 1988
    Assignee: Bio-Metric Systems, Inc.
    Inventor: Patrick E. Guire
  • Patent number: 4722891
    Abstract: Recombinant E. coli clones which cell surface-express Legionella pneumophila antigens, a method for utilizing these clones for the detection of Legionella antibodies in a clinical sample, and a method for isolation of mono-specific anti-Legionella antibodies are disclosed. The recombinant clones are produced by ligating fragmented Legionella DNA to pBR322 which is then used to transform the appropriate E. coli host. Clones that cell surface-express individual Legionella antigens are selected by screening cellularly intact clones using anti-Legionella antibodies to probe for cell surface expression. An enzyme-linked immunosorbant assay (ELISA) is disclosed which utilizes the Legionella antigen-expressing clones to detect anti-Legionella antibodies.
    Type: Grant
    Filed: June 20, 1984
    Date of Patent: February 2, 1988
    Assignee: Board of Regents, The University of Texas System
    Inventors: David J. Drutz, Barry I. Eisenstein, N. Cary Engleberg
  • Patent number: 4687841
    Abstract: Novel peptide hydroxamic acid derivatives having useful collagenase inhibitory activity and capable of forming affinity resins for the purification of vertebrate collagenase are defined by the following structural formula:R-Pro-Leu-Gly-NHOHwherein R=H or N-protecting group or agarose.
    Type: Grant
    Filed: October 18, 1985
    Date of Patent: August 18, 1987
    Assignee: Monsanto Company
    Inventors: Curtis A. Spilburg, William McC. Moore
  • Patent number: 4656252
    Abstract: Amidobiotin extender compounds useful, for example, in avidin-biotin multiple-layering process, which compounds include caproylamidobiotin-NHS ester, caproylamidobiotin-horse radish peroxidase, caproylamidobiotinribonuclease and caproylamidobiotin-alkaline phosphatase (B-ALP).
    Type: Grant
    Filed: June 4, 1984
    Date of Patent: April 7, 1987
    Inventor: Roger W. Giese
  • Patent number: 4625014
    Abstract: A photo-cleavable compound for delivery and release of a biologically active substance to selected target cells; the compound includes a binding partner for a specific cell-surface receptor of those target cells, the biologically active substance to be delivered, and a photo-cleavable bridge between the binding partner and the biologically active substance. When the compound is exposed to a heterogeneous population of target and non-target cells, it binds selectively to the receptors on the surface of the target cells. Exposing the compound to light of selected wave length cleaves it, yielding the active substance.
    Type: Grant
    Filed: July 10, 1984
    Date of Patent: November 25, 1986
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter D. Senter, John M. Lambert, Walter A. Blattler